Israel approves patent application for universal flu vaccine

Israel recently approved a patent application for a new universal flu vaccine developed by BiondVax Pharmaceuticals Ltd., which will serve to expand and improve the company's international intellectual property portfolio.

The approval, which came from the Israeli Intellectual Property Office, applies to the MultiMeric MultiEpitope Polypeptide Influenza Vaccine (M-001) and related polypeptides. The company has already gained patent protection in several European nations and Australia, China, Hong Kong, Japan, Korea, Mexico, Russia and the United States.

The vaccine, part of the company’s larger patent group, is an effort to provide broad protection against influenza strains. The researchers want to make a series of vaccines that will give long-lasting protection. The company aims for the vaccine to be effective against multi-strain, multi-season, seasonal, and pandemic influenza strains.

"We are very pleased that the Israeli patent authorities accepted the uniqueness of our universal flu vaccine solution, approving this main patent of BiondVax,” CEO Ron Babecoff said. “Our solution is patent-protected in many of the countries where we believe our vaccine will provide increased protection to the local population from flu."

Organizations in this Story


Want to get notified whenever we write about BiondVax ?
Next time we write about BiondVax, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.